Trade Evotec AG - EVT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.070 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.022102% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000121% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 5% | ||||||||
Stock exchange | Germany | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Evotec SE ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 13.265 |
Open* | 13.065 |
1-Year Change* | -31.49% |
Day's Range* | 12.995 - 13.285 |
52 wk Range | 14.10-24.44 |
Average Volume (10 days) | 1.22M |
Average Volume (3 months) | 12.25M |
Market Cap | 2.58B |
P/E Ratio | -100.00K |
Shares Outstanding | 176.94M |
Revenue | 820.80M |
EPS | -0.54 |
Dividend (Yield %) | N/A |
Beta | 0.98 |
Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 17, 2024 | 13.175 | 0.050 | 0.38% | 13.125 | 13.305 | 12.855 |
Apr 16, 2024 | 13.265 | -0.170 | -1.27% | 13.435 | 13.545 | 13.135 |
Apr 15, 2024 | 13.770 | 0.190 | 1.40% | 13.580 | 14.010 | 13.525 |
Apr 12, 2024 | 13.730 | -0.050 | -0.36% | 13.780 | 14.300 | 13.600 |
Apr 11, 2024 | 13.255 | -0.040 | -0.30% | 13.295 | 13.605 | 12.735 |
Apr 10, 2024 | 13.465 | -0.935 | -6.49% | 14.400 | 14.510 | 13.385 |
Apr 9, 2024 | 14.390 | 0.090 | 0.63% | 14.300 | 14.550 | 14.270 |
Apr 8, 2024 | 14.480 | 0.600 | 4.32% | 13.880 | 14.590 | 13.810 |
Apr 5, 2024 | 13.850 | -0.050 | -0.36% | 13.900 | 13.910 | 13.650 |
Apr 4, 2024 | 14.070 | 0.040 | 0.29% | 14.030 | 14.160 | 13.790 |
Apr 3, 2024 | 14.020 | 0.010 | 0.07% | 14.010 | 14.100 | 13.650 |
Apr 2, 2024 | 14.030 | -0.280 | -1.96% | 14.310 | 14.370 | 13.930 |
Mar 28, 2024 | 14.500 | 0.205 | 1.43% | 14.295 | 14.730 | 14.100 |
Mar 27, 2024 | 14.300 | 0.620 | 4.53% | 13.680 | 14.420 | 13.680 |
Mar 26, 2024 | 13.770 | 0.350 | 2.61% | 13.420 | 13.915 | 13.270 |
Mar 25, 2024 | 13.505 | -0.075 | -0.55% | 13.580 | 13.620 | 13.355 |
Mar 22, 2024 | 13.650 | 0.440 | 3.33% | 13.210 | 13.655 | 13.210 |
Mar 21, 2024 | 13.365 | -0.460 | -3.33% | 13.825 | 14.000 | 13.185 |
Mar 20, 2024 | 13.600 | 0.055 | 0.41% | 13.545 | 13.685 | 13.395 |
Mar 19, 2024 | 13.400 | 0.355 | 2.72% | 13.045 | 13.440 | 12.905 |
Evotec AG Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, April 24, 2024 | ||
Time (UTC) 05:00 | Country DE
| Event Full Year 2023 Evotec SE Earnings Release Full Year 2023 Evotec SE Earnings ReleaseForecast -Previous - |
Time (UTC) 10:59 | Country DE
| Event Full Year 2023 Evotec SE Earnings Call Full Year 2023 Evotec SE Earnings CallForecast -Previous - |
Wednesday, May 15, 2024 | ||
Time (UTC) 10:59 | Country DE
| Event Evotec SE at Bank of America Health Care Conference Evotec SE at Bank of America Health Care ConferenceForecast -Previous - |
Wednesday, May 22, 2024 | ||
Time (UTC) 05:00 | Country DE
| Event Q1 2024 Evotec SE Earnings Release Q1 2024 Evotec SE Earnings ReleaseForecast -Previous - |
Time (UTC) 10:59 | Country DE
| Event Q1 2024 Evotec SE Earnings Call Q1 2024 Evotec SE Earnings CallForecast -Previous - |
Monday, June 10, 2024 | ||
Time (UTC) 10:59 | Country DE
| Event Evotec SE Annual Shareholders Meeting Evotec SE Annual Shareholders MeetingForecast -Previous - |
Wednesday, June 19, 2024 | ||
Time (UTC) 10:59 | Country DE
| Event Evotec SE Annual Shareholders Meeting Evotec SE Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 751.448 | 618.034 | 500.924 | 446.437 | 375.405 |
Revenue | 751.448 | 618.034 | 500.924 | 446.437 | 375.405 |
Cost of Revenue, Total | 577.383 | 466.491 | 375.181 | 313.546 | 263.389 |
Gross Profit | 174.065 | 151.543 | 125.743 | 132.891 | 112.016 |
Total Operating Expense | 724.824 | 588.901 | 452.368 | 383.843 | 297.942 |
Selling/General/Admin. Expenses, Total | 156.19 | 105.445 | 77.205 | 66.546 | 57.012 |
Research & Development | 76.642 | 72.2 | 63.945 | 58.432 | 35.619 |
Unusual Expense (Income) | -5.774 | 12.546 | 3.244 | 11.919 | -11.036 |
Other Operating Expenses, Total | -79.617 | -67.781 | -67.207 | -66.6 | -47.042 |
Operating Income | 26.624 | 29.133 | 48.556 | 62.594 | 77.463 |
Interest Income (Expense), Net Non-Operating | -179.854 | 208.106 | -22.925 | -6.102 | -5.602 |
Other, Net | -0.727 | -0.259 | 0.209 | 0.07 | 0.138 |
Net Income Before Taxes | -153.957 | 236.98 | 25.84 | 56.562 | 71.999 |
Net Income After Taxes | -175.655 | 215.51 | 6.278 | 37.228 | 84.056 |
Minority Interest | 0 | 0 | 0 | 0.844 | 0.116 |
Net Income Before Extra. Items | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Net Income | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Income Available to Common Excl. Extra. Items | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Income Available to Common Incl. Extra. Items | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Diluted Net Income | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Diluted Weighted Average Shares | 176.674 | 166.406 | 153.752 | 149.726 | 147.482 |
Diluted EPS Excluding Extraordinary Items | -0.99423 | 1.29509 | 0.04083 | 0.25428 | 0.57073 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -1.01547 | 1.36365 | 0.05455 | 0.30667 | 0.52209 |
Dilution Adjustment | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 170.279 | 213.556 | 240.689 | 173.884 | 172.203 |
Revenue | 170.279 | 213.556 | 240.689 | 173.884 | 172.203 |
Cost of Revenue, Total | 123.956 | 160.319 | 158.233 | 145.464 | 141.308 |
Gross Profit | 46.323 | 53.237 | 82.456 | 28.42 | 30.895 |
Total Operating Expense | 206.567 | 201.041 | 197.229 | 187.413 | 175.973 |
Selling/General/Admin. Expenses, Total | 45.609 | 42.583 | 46.332 | 42.462 | 35.83 |
Research & Development | 12.377 | 18.486 | 21.322 | 18.482 | 18.725 |
Other Operating Expenses, Total | 24.625 | -20.347 | -22.884 | -18.995 | -19.89 |
Operating Income | -36.288 | 12.515 | 43.46 | -13.529 | -3.77 |
Interest Income (Expense), Net Non-Operating | 5.261 | -6.203 | -60.362 | -29.806 | -20.131 |
Other, Net | 10.59 | -12.527 | -0.622 | -0.029 | -0.435 |
Net Income Before Taxes | -20.437 | -6.215 | -17.524 | -43.364 | -24.336 |
Net Income After Taxes | -14.929 | -13.898 | -27.201 | -47.275 | -27.937 |
Net Income Before Extra. Items | -14.929 | -13.898 | -27.201 | -47.275 | -27.937 |
Net Income | -14.929 | -13.898 | -27.201 | -47.275 | -27.937 |
Income Available to Common Excl. Extra. Items | -14.929 | -13.899 | -27.201 | -47.275 | -27.937 |
Income Available to Common Incl. Extra. Items | -14.929 | -13.899 | -27.201 | -47.275 | -27.937 |
Diluted Net Income | -14.929 | -13.899 | -27.201 | -47.275 | -27.937 |
Diluted Weighted Average Shares | 176.936 | 176.936 | 176.589 | 176.703 | 176.703 |
Diluted EPS Excluding Extraordinary Items | -0.08438 | -0.07855 | -0.15404 | -0.26754 | -0.1581 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -0.08438 | -0.07855 | -0.17529 | -0.26754 | -0.1581 |
Unusual Expense (Income) | -5.774 | 0 | 0 | ||
Minority Interest | 0 | ||||
Total Adjustments to Net Income | -0.001 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1073.67 | 1100.94 | 658.844 | 469.53 | 249.769 |
Cash and Short Term Investments | 729.983 | 858.498 | 492.634 | 321.662 | 149.879 |
Cash & Equivalents | 415.155 | 699.326 | 422.58 | 277.034 | 109.055 |
Short Term Investments | 314.828 | 159.172 | 70.054 | 44.628 | 40.824 |
Total Receivables, Net | 256.737 | 176.754 | 122.221 | 117.844 | 74.772 |
Accounts Receivable - Trade, Net | 199.169 | 150.692 | 91.612 | 93.702 | 58.851 |
Total Inventory | 29.825 | 25.793 | 13.585 | 10.749 | 5.66 |
Prepaid Expenses | 40.178 | 19.21 | 9.258 | 9.166 | 8.451 |
Other Current Assets, Total | 16.948 | 20.685 | 21.146 | 10.109 | 11.007 |
Total Assets | 2257.25 | 2235.16 | 1462.34 | 1180.91 | 771.883 |
Property/Plant/Equipment, Total - Net | 650.201 | 484.597 | 337.297 | 239.229 | 90.519 |
Property/Plant/Equipment, Total - Gross | 920.81 | 686.086 | 481.879 | 350.415 | 164.143 |
Accumulated Depreciation, Total | -270.609 | -201.489 | -144.582 | -111.186 | -73.624 |
Goodwill, Net | 274.819 | 257.569 | 247.37 | 255.919 | 220.791 |
Intangibles, Net | 23.819 | 30.851 | 98.036 | 116.994 | 122.989 |
Long Term Investments | 150.332 | 287.009 | 59.021 | 41.252 | 28.99 |
Note Receivable - Long Term | 70.293 | 55.966 | 36.485 | 22.718 | 14.601 |
Other Long Term Assets, Total | 14.112 | 18.229 | 25.284 | 35.27 | 44.224 |
Total Current Liabilities | 337.706 | 324.516 | 208.459 | 178.955 | 196.275 |
Accounts Payable | 97.277 | 72.598 | 42.549 | 31.319 | 31.137 |
Accrued Expenses | 47.49 | 33.983 | 34.728 | 29.174 | 25.67 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 16.381 | 50.609 | 30.008 | 20.731 | 56.919 |
Other Current Liabilities, Total | 176.558 | 167.326 | 101.174 | 97.731 | 82.549 |
Total Liabilities | 1070.06 | 857.476 | 737.881 | 703.883 | 347.879 |
Total Long Term Debt | 490.293 | 462.308 | 461.957 | 442.368 | 57.546 |
Long Term Debt | 328.295 | 326.344 | 331.019 | 324.886 | 54.68 |
Capital Lease Obligations | 161.998 | 135.964 | 130.938 | 117.482 | 2.866 |
Deferred Income Tax | 18.524 | 17.688 | 20.399 | 21.199 | 21.517 |
Minority Interest | 0 | 0 | 0 | 0 | 0.876 |
Other Liabilities, Total | 223.54 | 52.964 | 47.066 | 61.361 | 71.665 |
Total Equity | 1187.18 | 1377.69 | 724.456 | 477.029 | 424.004 |
Common Stock | 176.953 | 176.608 | 163.915 | 150.903 | 149.063 |
Additional Paid-In Capital | 1440.01 | 1430.14 | 1030.7 | 786.865 | 783.154 |
Retained Earnings (Accumulated Deficit) | -392.377 | -216.421 | -432.639 | -441.177 | -481.013 |
Unrealized Gain (Loss) | -21.113 | 3.053 | 4.26 | 4.565 | 6.002 |
Other Equity, Total | -16.289 | -15.691 | -41.782 | -24.127 | -33.202 |
Total Liabilities & Shareholders’ Equity | 2257.25 | 2235.16 | 1462.34 | 1180.91 | 771.883 |
Total Common Shares Outstanding | 176.703 | 176.358 | 163.665 | 150.653 | 148.813 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 939.198 | 1026.45 | 1073.67 | 1095.82 | |
Cash and Short Term Investments | 619.18 | 632.973 | 729.983 | 828.795 | |
Cash & Equivalents | 499.366 | 459.752 | 415.155 | 463.913 | |
Short Term Investments | 119.814 | 173.221 | 314.828 | 364.882 | |
Total Receivables, Net | 219.371 | 291.301 | 256.737 | 187.997 | |
Accounts Receivable - Trade, Net | 161.105 | 228.955 | 199.169 | 140.631 | |
Total Inventory | 31.906 | 32.612 | 29.825 | 30.874 | |
Prepaid Expenses | 68.741 | 69.563 | 57.126 | 48.15 | |
Total Assets | 2254.51 | 2301.22 | 2257.25 | 2262.66 | |
Property/Plant/Equipment, Total - Net | 763.899 | 721.136 | 650.201 | 600.499 | |
Goodwill, Net | 274.819 | 278.417 | |||
Intangibles, Net | 291.055 | 292.612 | 23.819 | 25.736 | |
Long Term Investments | 151.62 | 160.842 | 150.332 | 189.245 | |
Note Receivable - Long Term | 98.685 | 88.8 | 70.293 | 56.911 | |
Other Long Term Assets, Total | 10.052 | 11.382 | 14.112 | 16.039 | |
Total Current Liabilities | 434.045 | 488.107 | 337.706 | 340.802 | |
Accounts Payable | 96.774 | 106.038 | 97.277 | 83.965 | |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
Current Port. of LT Debt/Capital Leases | 144.287 | 151.638 | 16.381 | 14.108 | |
Other Current Liabilities, Total | 192.984 | 230.431 | 224.048 | 242.729 | |
Total Liabilities | 1113.69 | 1126.93 | 1070.06 | 1034.14 | |
Total Long Term Debt | 444.455 | 382.509 | 490.293 | 477.984 | |
Long Term Debt | 444.455 | 382.509 | 328.295 | 326.776 | |
Capital Lease Obligations | 161.998 | 151.208 | |||
Deferred Income Tax | 18.603 | 19.13 | 18.524 | 17.179 | |
Other Liabilities, Total | 216.587 | 237.188 | 223.54 | 198.173 | |
Total Equity | 1140.82 | 1174.29 | 1187.18 | 1228.53 | |
Common Stock | 177.186 | 177.186 | 176.953 | 176.953 | |
Additional Paid-In Capital | 1446.47 | 1445.36 | 1440.01 | 1437.55 | |
Retained Earnings (Accumulated Deficit) | -482.836 | -448.256 | -392.377 | -364.631 | |
Other Equity, Total | -16.289 | -21.348 | |||
Total Liabilities & Shareholders’ Equity | 2254.51 | 2301.22 | 2257.25 | 2262.66 | |
Total Common Shares Outstanding | 176.936 | 176.936 | 176.703 | 176.703 | |
Unrealized Gain (Loss) | -21.113 | ||||
Minority Interest | 0 | 0 | 0 | 0 | |
Other Current Assets, Total | 0.001 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -175.655 | 215.51 | 6.252 | 37.228 | 84.056 |
Cash From Operating Activities | 203.106 | 122.237 | 44.721 | 42.216 | 156.24 |
Cash From Operating Activities | 72.677 | 55.596 | 42.122 | 36.456 | 19.288 |
Amortization | 8.982 | 12.012 | 13.936 | 12.349 | 12.005 |
Deferred Taxes | 7.722 | 5.066 | 7.49 | 6.706 | -26.117 |
Non-Cash Items | 195.391 | -165.371 | 23.865 | 24.342 | 0.364 |
Cash Taxes Paid | 18.5 | -6.028 | 9.796 | 2.417 | 3.596 |
Cash Interest Paid | 9.798 | 5.429 | 3.465 | 4.49 | 2.279 |
Changes in Working Capital | 93.989 | -0.576 | -48.944 | -74.865 | 66.644 |
Cash From Investing Activities | -415.823 | -243.855 | -155.089 | -86.634 | -39.13 |
Capital Expenditures | -181.354 | -118.943 | -99.072 | -31.905 | -27.867 |
Other Investing Cash Flow Items, Total | -234.469 | -124.912 | -56.017 | -54.729 | -11.263 |
Cash From Financing Activities | -52.414 | 398.43 | 246.409 | 211.263 | -77.764 |
Financing Cash Flow Items | |||||
Issuance (Retirement) of Stock, Net | 0.699 | 404.322 | 251.564 | 1.901 | 1.578 |
Issuance (Retirement) of Debt, Net | -53.113 | -5.892 | -5.155 | 209.362 | -79.342 |
Foreign Exchange Effects | -19.04 | -0.066 | 9.505 | 1.134 | 2.692 |
Net Change in Cash | -284.171 | 276.746 | 145.546 | 167.979 | 42.038 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -175.655 | -148.454 | -101.179 | -73.242 | 215.51 |
Cash From Operating Activities | 203.106 | 236.633 | 240.607 | 63.618 | 122.237 |
Changes in Working Capital | 378.761 | 385.087 | 341.786 | 136.86 | -93.273 |
Cash From Investing Activities | -415.823 | -435.034 | -206.857 | -95.732 | -243.855 |
Capital Expenditures | -181.354 | -157.21 | -81.371 | -42.921 | -118.943 |
Other Investing Cash Flow Items, Total | -234.469 | -277.824 | -125.486 | -52.811 | -124.912 |
Cash From Financing Activities | -52.414 | -50.454 | -45.805 | -5.279 | 398.43 |
Issuance (Retirement) of Stock, Net | 0.699 | 0.355 | 0.7 | 0.345 | 404.322 |
Issuance (Retirement) of Debt, Net | -53.113 | -50.809 | -46.505 | -5.624 | -5.892 |
Foreign Exchange Effects | -19.04 | 13.442 | 9.721 | -1.445 | -0.066 |
Net Change in Cash | -284.171 | -235.413 | -2.334 | -38.838 | 276.746 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Evotec Company profile
About Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Evotec SE revenues increased 20% to EUR431M. Net income increased from EUR5.8M to EUR247M. Revenues reflect EVT Execute segment increase of 22% to EUR329M, EVT Innovate segment increase of 36% to EUR101.9M, United States segment increase of 32% to EUR142.9M, Others segment increase of 30% to EUR47.5M, United Kingdom segment increase of 8% to EUR47.2M.
Industry: | Biotechnology & Medical Research (NEC) |
Essener Bogen 7
HAMBURG
HAMBURG 22419
DE
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com